Galvus Safety Trial Reconsidered In Light Of Novartis Cost Concerns

Novartis' NDA for its oral type 2 diabetes drug Galvus (vildagliptin) will remain in a holding pattern in the U.S. until the firm has a clearer idea of whether it can gain FDA approval without excessive expenditures to gather additional safety data